DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dkwpmr/peripheral_tcell) has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AB Science
- Affimed Therapeutics AG
- Bayer AG
- Celgene Corporation
- Eisai Co., Ltd.
- Incyte Corporation
- Karyopharm Therapeutics, Inc.
- Kyowa Hakko Kirin Co., Ltd.
- Millennium Pharmaceuticals, Inc.
- Mundipharma International Limited
- Onxeo SA
- Sanofi
- Solasia Pharma K.K.
- Spectrum Pharmaceuticals, Inc.
- TG Therapeutics, Inc.
Drug Profiles
- AFM-13
- alemtuzumab
- alisertib
- belinostat
- copanlisib
- darinaparsin
- denileukin diftitox
- forodesine hydrochloride
- lenalidomide
- masitinib
- mogamulizumab
- pralatrexate
- romidepsin
- ruxolitinib phosphate
- selinexor
- SH-7129
- TGR-1202
For more information visit http://www.researchandmarkets.com/research/dkwpmr/peripheral_tcell
